JP2014527969A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527969A5
JP2014527969A5 JP2014530945A JP2014530945A JP2014527969A5 JP 2014527969 A5 JP2014527969 A5 JP 2014527969A5 JP 2014530945 A JP2014530945 A JP 2014530945A JP 2014530945 A JP2014530945 A JP 2014530945A JP 2014527969 A5 JP2014527969 A5 JP 2014527969A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014530945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/055887 external-priority patent/WO2013043580A2/en
Publication of JP2014527969A publication Critical patent/JP2014527969A/ja
Publication of JP2014527969A5 publication Critical patent/JP2014527969A5/ja
Ceased legal-status Critical Current

Links

JP2014530945A 2011-09-19 2012-09-18 改変クレアチン化合物 Ceased JP2014527969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536280P 2011-09-19 2011-09-19
US61/536,280 2011-09-19
PCT/US2012/055887 WO2013043580A2 (en) 2011-09-19 2012-09-18 Modified creatine compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111480A Division JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Publications (2)

Publication Number Publication Date
JP2014527969A JP2014527969A (ja) 2014-10-23
JP2014527969A5 true JP2014527969A5 (https=) 2015-11-12

Family

ID=46982949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530945A Ceased JP2014527969A (ja) 2011-09-19 2012-09-18 改変クレアチン化合物
JP2017111480A Pending JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017111480A Pending JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Country Status (8)

Country Link
US (1) US9434753B2 (https=)
EP (1) EP2758411A2 (https=)
JP (2) JP2014527969A (https=)
CN (1) CN103889993B (https=)
AU (1) AU2012312654B2 (https=)
CA (1) CA2849073A1 (https=)
HK (1) HK1200459A1 (https=)
WO (1) WO2013043580A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20121098A1 (it) * 2012-12-18 2014-06-19 Univ Degli Studi Genova Procedimento per sintetizzare derivati della creatina
AU2014227952A1 (en) 2013-03-15 2015-10-22 Gencia Corporation Compositions and methods for treating conditions that affect epidermis
US20160289175A1 (en) * 2013-11-05 2016-10-06 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
US9617230B2 (en) * 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US11021501B2 (en) 2015-03-30 2021-06-01 Farmington Pharma Development Creatine phosphate analog prodrugs, compositions and methods of use thereof
US10883978B2 (en) * 2017-01-31 2021-01-05 Agilent Technologies, Inc. Method and device for calibration of biological flux
JP6919923B2 (ja) * 2017-08-04 2021-08-18 国立大学法人金沢大学 微小空間の加温方法及び発熱体
KR102678696B1 (ko) 2017-12-01 2024-06-27 울트라제닉스 파마수티컬 인코포레이티드 크레아틴 전구약물, 조성물과 이의 사용 방법
KR101920902B1 (ko) * 2017-12-27 2018-11-21 전남대학교 산학협력단 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도
WO2021085906A1 (ko) * 2019-10-30 2021-05-06 주식회사 퓨전바이오텍 미토콘드리아 표적 화합물 및 이를 포함하는 노화 관련 질환의 치료 또는 예방을 위한 조성물
CN115417898B (zh) * 2022-08-02 2024-03-26 浙江工业大学 一种三苯基鏻单体化合物及其制备方法与在制备核酸递送纳米载体中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU4151996A (en) 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US20060128671A1 (en) 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
CA2327095A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
JP2002523412A (ja) 1998-08-25 2002-07-30 ザ ユーエイビー リサーチ ファウンデイション 細菌nadシンテターゼ阻害剤
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
ES2223464T3 (es) 1999-02-01 2005-03-01 Eisai Co., Ltd. Compuestos adyuvantes inmunologicos.
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6355616B1 (en) * 1999-06-25 2002-03-12 Xoma (Us) Technology Ltd. Derivative compounds derived from or based on bactericidal/permeability-increasing protein
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
CA2423902A1 (en) 2000-09-27 2003-03-26 Ajinomoto Co., Inc. Benzodiazepine derivative
JP2005298343A (ja) 2002-03-27 2005-10-27 Ajinomoto Co Inc ベンゾジアゼピン誘導体
JP2003321499A (ja) * 2002-04-30 2003-11-11 Internatl Reagents Corp ミトコンドリアクレアチンキナーゼ抗体
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
BRPI0413742B8 (pt) 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
CN1997403A (zh) 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
US7915230B2 (en) 2005-05-17 2011-03-29 Molecular Transfer, Inc. Reagents for transfection of eukaryotic cells
US20070066572A1 (en) * 2005-09-14 2007-03-22 Kalyanaraman Balaraman Neuroprotection by positively-charged nitroxides
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2604255B1 (en) 2006-05-05 2017-10-25 Molecular Transfer, Inc. Novel reagents for transfection of eukaryotic cells
WO2008039085A1 (en) * 2006-09-28 2008-04-03 University Of Otago Triphenylphosphonium thionitrite nitric oxide donors
CN101848918A (zh) * 2007-09-07 2010-09-29 吉奇亚公司 线粒体组合物及其用途
CA2714700C (en) 2008-02-22 2013-07-30 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
NZ602579A (en) 2008-03-14 2013-12-20 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
CN102459291B (zh) * 2009-04-27 2015-11-25 Mcw研究基金会股份有限公司 神经保护性化合物和它们的应用
US20110021362A1 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
EP3266462A1 (en) 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections

Similar Documents

Publication Publication Date Title
JP2014527969A5 (https=)
MX2022005399A (es) Compuestos.
JP2010100637A5 (https=)
JP2014043462A5 (https=)
JP2008522981A5 (https=)
JP2019512478A5 (https=)
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
MX377255B (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
JP2013530179A5 (https=)
RU2009106934A (ru) Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента
Majer et al. Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2-phosphonomethylpentanedioic acid (2-PMPA)
AU2012312654B2 (en) Modified creatine compounds
CA2750413A1 (en) Hydroxamic acid derivatives
ME03391B (me) Jedinjenje (6s,9as)-n-benzil-6-((4-hidroksifenil)metil)-4,7-diokso-8-((6-(3-(piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-2-(prop-2-en-1-il)-oktahidro-1h-pirazino(2,1-c)(1,2,4)triazin-1-karboksamida
JP2017518304A5 (https=)
JP2009544582A5 (https=)
HRP20190980T1 (hr) Derivati predlijeka (e)-n-metil-n((3-metilbenzofuran-2 il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
JP2015529228A5 (https=)
EA202090514A1 (ru) Противовирусное средство против гепатита в
WO2017024009A1 (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
JP2018530582A5 (https=)
JP2012021006A5 (https=)
JP2017537886A5 (https=)
UA114405C2 (uk) Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу
RU2012135698A (ru) Способ и композиция